| Literature DB >> 8485265 |
Abstract
It would be ideal to treat inflammatory bowel disease with topical corticosteroids that are either not absorbed through the mucosa, or have a substantial first-pass hepatic metabolism. The topical use of hydrocortisone, prednisolone-21-phosphate or betamethasone is often associated with systemic side-effects. Newer corticosteroid preparations (prednisolone metasulphobenzoate, tixocortol pivalate, fluticasone propionate, beclomethasone dipropionate and budesonide) are usually associated with minimal systemic corticosteroid activity. This article reviews the clinical activity and safety of these newer preparations.Entities:
Mesh:
Substances:
Year: 1993 PMID: 8485265 DOI: 10.1111/j.1365-2036.1993.tb00080.x
Source DB: PubMed Journal: Aliment Pharmacol Ther ISSN: 0269-2813 Impact factor: 8.171